Supplementary Table S4 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S4. Response rates (mid-treatment, end-of-treatment and best response) in the overall population and various subgroups.
Authors: Holger N. Lode, Nikolai Siebert, Dominique Valteau-Couanet, Alberto Garaventa, Adela Canete, John Anderson, Isaac Yaniv, Shifra Ash, Juliet Gray, Thomas Klingebiel, Hans Loibner, Roberto Luksch, Carla Manzitti, Jean Marie Michon, Cormac Owens, Ulrike Pötschger, Sascha Troschke-Meurer, Evgenia Glogova, Ruth Ladenstein
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413905616